Arena Pharma (ARNA) Says Etrasimod Accepted for Late-Breaking Presentation at UEGW Meeting

October 11, 2016 8:30 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET. The meeting is taking place October 15-19 in Vienna, Austria. The data will also be published in the December issue of United European Gastroenterology Journal, a peer-reviewed medical journal providing coverage of both translational as well as clinical studies from all fields of gastroenterology.

The following abstract will be presented:

Lecture: LB20 - RECEPTOR PROFILE AND EFFICACY OF ETRASIMOD (APD334), AN ORAL, NEXT-GENERATION SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR IN DEVELOPMENT FOR ULCERATIVE COLITIS Session: 807 - Improving therapy in IBDSession Type: Late Breaking AbstractsDate: Tuesday, October 18, 2016



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Add Your Comment